Lee Ainslie Atara Biotherapeutics, Inc. Transaction History

Maverick Capital LTD

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$2.8 - $5.46 $840 - $1,638	-300 Reduced -0.0%	6,290,713 $18.2 Million
Q4 2022 Feb 14, 2023	SELL	$2.85 - $5.18 $4.46 Million - $8.11 Million	-1,564,811 Reduced 19.92%	6,291,013 $20.6 Million
Q3 2021 Nov 15, 2021	BUY	$11.99 - $17.9 $1.81 Million - $2.71 Million	151,148 Added 1.96%	7,855,824 $141 Million
Q2 2021 Aug 16, 2021	BUY	$12.89 - $16.58 $12.4 Million - $16 Million	965,274 Added 14.32%	7,704,676 $120 Million
Q1 2021 May 17, 2021	SELL	$14.0 - $20.72 $8.19 Million - $12.1 Million	-585,137 Reduced 7.99%	6,739,402 $96.8 Million
Q4 2020 Feb 16, 2021	BUY	$12.67 - $26.23 $7.33 Million - $15.2 Million	578,247 Added 8.57%	7,324,539 $144 Million
Q3 2020 Nov 16, 2020	SELL	$11.92 - $15.87 $93,095 - $123,944	-7,810 Reduced 0.12%	6,746,292 $87.4 Million
Q2 2020 Aug 14, 2020	BUY	$7.53 - $14.93 $11.7 Million - $23.2 Million	1,554,205 Added 29.89%	6,754,102 $98.4 Million
Q1 2020 May 15, 2020	BUY	$5.69 - $17.78 $1.37 Million - $4.29 Million	241,466 Added 4.87%	5,199,897 $44.3 Million
Q4 2019 Feb 14, 2020	SELL	$10.89 - $16.79 $1.58 Million - $2.44 Million	-145,532 Reduced 2.85%	4,958,431 $81.7 Million
Q3 2019 Nov 14, 2019	BUY	$12.03 - $19.94 $34.5 Million - $57.3 Million	2,871,487 Added 128.62%	5,103,963 $72.1 Million
Q2 2019 Aug 14, 2019	BUY	$19.05 - $41.04 $25.9 Million - $55.9 Million	1,361,712 Added 156.38%	2,232,476 $44.9 Million
Q1 2019 May 15, 2019	BUY	$28.4 - $41.74 $24.7 Million - $36.3 Million	870,764 New	870,764 $34.6 Million

2.89M

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $1.08B
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

Get notified when there are updates to the investment portfolio of Maverick Capital LTD, based on Form 13F filings with the SEC.

Stay updated on Maverick Capital LTD and Lee Ainslie with notifications on news.